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synthesis [1–3]. The diphosphate derivative inhibits Magnusen Clinical Center, NIH (Bethesda, MD,
ribonucleotide reductase, thereby depleting the en- USA).
dogenous deoxyribonucleotide triphosphate pools.
The triphosphate derivative is incorporated into DNA Standard solutions
and subsequently interferes with DNA chain elonga-
tion. Gemcitabine is deaminated to the inactive Stock solutions of dFdC, dFdU and FdC at
metabolite 29,29-difluorodeoxyuridine (dFdU) by cy- concentrations of 10 mM (2.63 mg/ml), 7.57 mM (2
tidine deaminase. Gemcitabine is used clinically to mg/ml) and 10 mM (2.44 mg/ml), respectively,
treat a variety of solid tumors, particularly pan- were prepared in water; aliquots were stored at
creatic, bladder and non-small cell lung cancers. 230 8C. Calibration standards were prepared by
Preclinical studies conducted in our laboratory appropriate dilutions of the dFdC stock solutions
suggested that the combination of dFdC for 4 h with water to generate 103 calibration standards at
followed by a 24-h exposure to 5-fluoro-29-deoxy- concentrations ranging between 5 and 1500 mM;
uridine (FdU) resulted in more than additive cytotox- aliquots were stored at 230 8C; dilutions of the
icity and enhanced DNA damage in a human colon dFdU stock solutions with water generated 103
cancer cell line [4]. Therefore, a Phase I trial of calibration standards ranging from 5 to 2270 mM.
weekly dFdC followed by a 24-h infusion of FdU Plasma calibration standards were made by adding
was designed. To permit determination of the plasma 50 ml of a 103 calibration standard solution to 0.5
levels of dFdC and dFdU in patient samples, a ml of plasma to give final concentrations upon
reversed-phase HPLC assay was developed. reconstitution of the extracted plasma sample that
ranged between 0.5 and 150 mM for dFdC or 0.5 and
227 mM for dFdU. Fifty microliters of 250 mM FdC
or 20 ml of 1 mM FdC was added to 0.5 ml plasma
Experimental conditions to give a final concentration of 25 or 40 mM (see
Section 3.1).
Chemicals
Sample preparation
The commercial formulation of gemcitabine hy-
drochloride (each vial contains 200 mg of gem- Standard curves were prepared in pooled plasma
citabine as the free base, 262.9 g/mol) was pur- which was placed on ice immediately upon thawing.
chased from Eli Lilly and Company (Indianapolis, Aliquots of 0.5-ml test plasma were placed in 12375
IN, USA). dFdU was generously provided by Lilly mm glass tubes on ice; calibration standards and 20
Research Laboratories though a material transfer ml of 1 mM internal standard were added. Glacial
agreement with the National Cancer Institute (NCI). acetic acid (50 ml) was added to decrease hydrogen
FdC (HPLC internal standard), was purchased from bonding between the nucleosides and proteins. After
Sigma (St Louis, MO, USA). Tetrahydrouridine the addition of 1 ml of acetonitrile, the samples were
(THU), an inhibitor of cytidine deaminase, was vortex-mixed. Following centrifugation at 800 g for
provided by the Drug Synthesis and Chemistry 15 min at 4 8C, the supernatant was removed. To
Branch, Developmental Therapeutics Program, Divi- improve the recovery (see Section 3.2), 1 ml of
sion of Cancer Treatment and Diagnosis, NCI, acetonitrile was added to the precipitate, the sample
National Institutes of Health (NIH), Bethesda, MD, was vortex-mixed followed by repeat centrifugation.
USA [5]. Glacial acetic acid (analytic reagent (AR) The supernatants were combined, and the sample
grade) and sodium acetate (AR grade) were from was evaporated to dryness using filtered compressed
Mallinckrodt (Paris, KY, USA). HPLC grade water, air in a 42 8C water bath in a Zymark TurboVap
methanol and acetonitrile were from Fisher (Fair (Hopkinton, MA, USA) and stored at 230 8C. On
Lawn, NJ, USA). All other chemicals were AR the day of analysis, the residue was re-suspended in
grade. Pooled donor plasma was obtained from the 0.5 ml HPLC water, incubated for 5 min in a 37 8C
Department of Transfusion Medicine, Warren G. water bath, and then clarified by centrifugation at
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12 000 g for 10 min at 20 8C. The resultant superna- return to 100% A and re-equilibration for 6 min.
tant was filtered though a 1-ml syringe fitted with a FdC, dFdC and dFdU were monitored at wave-
GHP 13-mm Acrodisc, 2-mm pore size, with mini- lengths of 282, 269 and 258 nm, respectively.
spike outlet (Pall Gelman Laboratory, Ann Arbor,
MI, USA). An aliquot of each sample was placed in Calculations
250-ml low volume glass inserts placed in 4-ml glass
vials (Waters, Milford, MA, USA) and loaded into a The ratios of the peak heights of dFdC or dFdU to
48-position carousel tray. The injection volume was FdC were calculated, which were then plotted versus
190 ml. The residuals of the reconstituted samples the nominal total amount of dFdC or dFdU in the
were stored at 230 8C in the event that repeat sample. The data were fitted using least squares
injection was needed. Because the calibration stan- linear regression with a weighting factor of 1 /y, not
dards were prepared in pre-chilled plasma on ice, the including the origin, using SigmaPlot 2001 (SPSS,
inclusion of THU (final concentration 1 mM) during Chicago, IL, USA). Analyte concentrations were
their preparation did not affect either the recovery or determined using the calibration lines thus generated.
peak heights of the analytes or internal standard.
Blood samples from patients receiving 1000 mg/ Recovery2
m of dFdC were obtained using 10-ml heparinized
tubes containing 10 nmol THU. The blood collection Plasma samples were prepared in triplicate con-
tubes were immediately placed on ice until centrifu-
taining six concentrations ranging from 0.5 to 100gation at 1000 g for 10 min at 4 8C. Aliquots of
mM of dFdC and dFdU; each sample contained aplasma were stored at 270 8C until analysis. Twenty fixed concentration of FdC (25 mM). Non-treated
microliters of 1 mM FdC were added to 0.5-ml
standards were samples in which the same con-
aliquots of plasma, and the samples were then
centration of the internal standard, dFdC or dFdUprepared as described above.
were prepared in water and not subjected to the
precipitation procedure. The percent absolute re-High-performance liquid chromatography with
covery was defined as the (peak height of thephotodiode array detection precipitated plasma standard4peak height of the
non-treated standard)3100%.The Waters chromatographic system (Milford,
MA, USA) was used consisting of a 600E Multi-
Validationsolvent Delivery System, a 717 plus Autosampler set
at 4 8C, a 996 Photodiode Array Detector and an
Concentrations of dFdC and dFdU were deter-in-line vacuum degasser. A Columbus C column18
mined by three calibration curves run over a 3-week˚(5-mm particle size, 110 A pore size, 15034.6 mm)
period to compare the observed with the theoreticalwas employed for the separations (Phenomenex,
concentration. To determine within-run variation,Torrance, CA, USA). The pre-column was a Waters
triplicate samples at six different concentrations ofC Nova-Pak Sentry guard column (4-mm particle18 dFdC and dFdU were prepared in human plasma,size). A Micron Millennia computer (Nampa, ID,
and the samples were injected on the same day.USA) was used to acquire data and perform the
Between-run variation was determined by injectinginitial data analysis using Millenium 32 software
triplicate samples prepared at three different con-version 3.2 (Waters).
centrations on three separate occasions.HPLC solvent A was 50 mM sodium acetate (pH
5.0) with 2% (v/v) methanol; solvent B was the
same buffer with 10% (v/v) methanol. Total flow- Stability of samples
rate was 1.5 ml /min and the column was at ambient
temperature. The following program was run: 100% The stability of the stock solutions of dFdC, dFdU
A for 17 min, a linear gradient of 100% A to 100% and FdC was tested by preparing three concen-
B over 14 min, 100% B for 2 min, and immediate trations of the compounds in water, and analyzing an
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aliquot immediately and after storage at room tem- a second acetonitrile precipitation improved the
perature and at 230 8C. absolute recoveries by about 17% over that achieved
with a single precipitation with 1 ml acetonitrile;
recovery with two sequential 1-ml precipitations wasAnalysis of patient plasma samples
also greater than a single precipitation with 2 ml
acetonitrile (data not shown). With the sample prepa-Patients were participating in an Institutional
ration described herein, the overall recovery of allReview Board-approved Phase I clinical trial involv-
three analytes from 0.5 ml plasma was $70% foring dFdC given as either a 1- or 2-h infusion
dFdC, $68% for FdC, and $82% for dFdU (Tablefollowed by a 24-h infusion of FdU weekly for 3 of
1).4 weeks. All patients gave written, informed consent.
A baseline plasma sample was obtained pre-therapy.
To provide an estimate of steady-state gemcitabine
Accuracy and precisionplasma concentrations, samples were obtained at 30,
40 and 50 min during the 1-h infusion, and at 90 and
Data from three calibration curves prepared with105 min during the 2-h infusion.
six standard concentrations of dFdC and dFdU with a
fixed FdC concentration that were examined over a
3-week period are shown in Table 2. The percent
Results coefficients of variation (% CV) for dFdC were
below 3% at concentrations $5 mM, and were below
High-performance liquid chromatography 10.2% for 1 and 0.5 mM. There was greater vari-
ability with dFdU: the %CV was 22.2% with 0.5
FdC, dFdC and dFdU were resolved from endog- mM, but was below 7% for higher concentrations
enous compounds with resulting retention times of with the exception of 5 mM (%CV 11.5%). The
213.660.5, 18.161.1 and 29.060.6 min, respectively. average r values for the three calibration curves
dFdC and dFdU were monitored at their optimal UV were above 0.998 for both dFdC and dFdU.
wavelengths, 269 and 258 nm, respectively, under Within-run variation was assessed using six con-
the experimental conditions as determined by spec- centrations of dFdC and dFdU with fixed concen-
tral analysis using the photodiode array detector. trations of FdC (25 mM) and THU (1 mM) prepared
Because an endogenous peak (that was not present in triplicate. The results of within-run variation were
when FdC stock solution was directly injected) determined by comparing the peak heights for dFdC,
eluted shortly after FdC, we compensated by increas- dFdU and FdC for these nine separate samples
ing the amount of the internal standard from 25 to 40 injected into the HPLC system on the same day. The
mM, and monitoring the peak height at 282 nm. coefficients of variation ranged from 1.1 to 6.0% for
These measures provided a greater peak height for dFdC, and were ,4.3% for dFdU and FdC (Table
FdC and allowed baseline resolution between FdC 3). Assessment of between-run variability was car-
and the adjacent endogenous peak (Fig. 2). THU is ried out subsequently using concentrations of dFdU
not detectable under the conditions used. and dFdC that would encompass the expected plasma
concentrations taken from patients during the 1- to
Recovery 2-h dFdC infusion. The coefficients of variation were
#5.1% for three compounds (Table 4).
Absolute recovery of FdC, dFdC and dFdU from
plasma was compared to non-extracted samples
prepared in water under identical concentrations. In Linearity
preliminary studies, it was determined that the
recovery was about 10% greater when the samples The assay was linear between 0.5 and 150 mM
were filtered though a GHP 0.2-mm syringe filter (0.13–39.4 mg/ml) for dFdC and 1 to 227 mM
compared to the use of a PVDF filter. Application of (0.26–60.0 mg/ml) for dFdU.
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Fig. 2. Chromatography and UV detection of dFdC and dFdU in the plasma of a patient 40 min after the start of a 1-h infusion of 1000
2
mg/m of dFdC. Identified peaks include the internal standard, dFdC and dFdU. The calculated plasma concentrations of dFdC and dFdU
were 23.7 and 59.2 mM, respectively.
Table 1
Absolute recovery of internal and calibration standards
Analyte 0.5 mM 1 mM 5 mM 10 mM 50 mM 150 mM
dFdC Mean 75.8 78.8 80.2 86.3 70.0 78.5
SD 1.2 0.9 1.2 3.5 2.6 4.7
%CV 1.6 1.1 1.5 4.1 3.8 6.0
dFdU Mean 95.2 86.4 87.4 81.8 87.5 101.4
SD 2.6 1.0 1.7 3.5 0.8 2.2
%CV 2.8 1.2 2.0 4.3 0.9 2.2
FdC Mean 68.3 76.2 67.9 83.4 68.0 75.8
SD 1.8 1.5 1.5 3.5 2.1 0.9
%CV 2.7 2.0 2.2 4.2 3.1 1.2
Triplicate samples of internal standard (fixed concentration of 25 mM) and calibration standards were prepared in both plasma and water.
The plasma was subjected to the sample preparation described in Section 2, whereas aliquots of the standards prepared in water were
directly injected into the HPLC without further processing.
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Table 2
Gemcitabine (dFdC) and 29,29-difluorodeoxyuridine (dFdU) calibration standards in human plasma
Concentration Measured dFdC (mM) dFdC Measured dFdU (mM) dFdU
(mM) (mean6SD) %CV (mean6SD) %CV
150 152.163.0 2.0 152.463.4 2.2
50 48.761.2 2.5 48.261.5 3.1
10 9.460.3 2.7 9.860.7 6.7
5 4.860.10 2.0 4.760.5 11.5
1 1.060.1 10.2 1.160.0 1.6
0.5 0.5360.05 8.8 0.5260.11 22.2
Calibration curve parameters dFdC dFdU
2
r 0.998960.0009 0.998560.0014
X-coefficient 0.07560.005 0.06760.016
Y-intercept 20.003860.0095 0.026260.0360
The data are from three calibration curves in human plasma done over a 3-week period. The internal standard concentration was 40 mM.
Table 3
Within-run precision for gemcitabine (dFdC) and 29,29-difluorodeoxyuridine (dFdU) in human plasma
Concentration dFdC dFdU 25 mM FdC
(mM) Peak height SD %CV Peak height SD %CV Peak height SD %CV
0 5 1917 73 3 8 2232 62 2 8 76 717 627 0 8
1 4614 274 5 9 5413 119 2 2 79 946 1571 2 0
5 22 625 334 1 5 21 226 422 2 0 76 761 1954 2 6
10 53 242 2186 4 1 40 011 1732 4 3 77 222 3214 4 2
50 223 332 3488 1 6 229 301 2037 0 9 73 603 5146 7 0
150 896 568 9901 1 1 600 932 7148 1 2 68 415 831 1 2
The data are from samples prepared in triplicate and injected during the same HPLC run.
Stability month, and at both 4 8C and room temperature for at
least 1 week (data not shown).
It has been reported that both gemcitabine and
dFdU are stable for at least 21 months at 270 8C in Testing of patient plasma samples
THU-treated human plasma, and that both analytes
were unaffected by three freeze–thaw cycles [8]. Plasma dFdC and dFdU concentrations were de-
Therefore, we did not repeat this analysis. In the termined as part of a Phase I trial of weekly dFdC
current study, stock solutions of 1 mM FdC, 1 mM, followed by infusional FdU. The plasma concen-
2100 and 10 mM dFdC, and 7.57 mM, 378.5 and trations for six patients each receiving 1000 mg/m
37.85 mM dFdU were stable at 230 8C for at least 1 dFdC as either a 1- or 2-h infusion are shown in Fig.
Table 4
Between-run precision for gemcitabine (dFdC) and 29,29-difluorodeoxyuridine (dFdU) in human plasma
Concentration (mM) dFdC dFdU 40 mM FdC
dFdC dFdU Peak height SD %CV Peak height SD %CV Peak height SD %CV
5 15 25 449 389 1 5 74 850 1755 2 4 107 342 3007 2 4
25 95 125 054 962 0 8 428 440 21 737 5 1 108 677 3053 2 8
100 227 524 059 10 345 2 0 1 009 497 39 371 3 9 112 268 1977 1 8
The data are from samples prepared in human plasma in triplicate and injected on three different days.
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acetate, or acetonitrile. We found that liquid–liquid
extraction with two sequential acetonitrile applica-
tions yielded the best recovery.
Several studies have been published that describe
analysis of dFdC and dFdU in plasma samples
obtained from cancer patients receiving gemcitabine
[6–10]. However, only a few employed an internal
standard and provided sufficient information to en-
sure method reproducibility [6,9]. The first validated
assay reported from researchers at Lilly Research
Laboratories used normal-phase HPLC with an
Alltech amino column [6]. The procedure required
sequential liquid–liquid extraction using both iso-
propanol and ethyl acetate followed by concentration
to dryness; the reconstituted residue was then filtered
Fig. 3. Plasma concentrations of dFdC and dFdU in patients though an ultra-free MC filter to remove insoluble
2
receiving 1000 mg/m gemcitabine. The data, shown as the material. The mobile phase represented an aqueous
mean6SD, are from six patients who each received either a 1-h or
mixture containing five different solvents.2-h infusion.
An additional published method used acetonitrile
precipitation for sample preparation, and an isocratic
3. There were no interfering endogenous peaks in the mobile phase of 15 mM ammonium acetate, pH 5.0,
pre-therapy samples under the conditions used. In all and acetonitrile (97.5:2.5, v /v) for 47 min followed
patients, dFdC and dFdU were detected at the by a linear increase to 15 mM ammonium acetate,
planned sampling times. The dFdC levels were pH 5.0, and acetonitrile (95:5, v /v) over 5 min [9].
similar at 30, 40 and 50 min in patients receiving a The latter solvent was run isocratically for 10 min
1-h infusion, and at 90 and 105 min in those followed by a linear return over 5 min to initial
receiving a 2-h infusion, suggesting the drug was at conditions. The column was allowed to equilibrate
or near steady-state. The average plasma levels for for 10 min prior to the next injection, for an overall
all time points for the 1-h infusion, 30.7 mM, was cycle time of 77 min to resolve dFdC, dFdU and the
about twofold higher than that observed with the 2-h internal standard, 29,29-difluorodeoxythymidine.
infusion, 15.2 mM. In contrast, the dFdU levels The current method employs reversed-phase
appeared to be increasing throughout the infusion, HPLC that offers a shorter cycling time (39 min),
and were on average 3.2- and 7.6-fold higher than partly due to the selection of the internal standard
the corresponding dFdC levels at the 50- and 105- FdC, which elutes sooner than dFdC and has similar
min sampling times after the start of a 1- and 2-h recovery. This method has proven useful in the
infusion, respectively. This observation is consistent analysis of samples from patients receiving dFdC
with a longer half-life for dFdU, which is cleared by given as a 1- or 2-h infusion weekly for 3 of 4
renal excretion, as opposed to the predominantly weeks. By using a smaller volume of plasma (0.1–
metabolic clearance of dFdC. 0.2 ml), the methodology described herein can also
be employed in the analysis of samples obtained
during a 30-min infusion of dFdC.
Discussion
In the process of developing the current method, R eferences
we evaluated several methods for sample prepara-
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